Citigroup Maintains Buy on Krystal Biotech, Lowers Price Target to $412
Benzinga Newsdesk 2 hours ago
Analyst RatingsNewsPrice Target
Citigroup analyst Yigal Nochomovitz maintains Krystal Biotech (NASDAQ:KRYS) with a Buy and lowers the price target from $416 to $412.
Citigroup analyst Yigal Nochomovitz maintains Krystal Biotech (NASDAQ:KRYS) with a Buy and lowers the price target from $416 to $412.